-
Mashup Score: 0
The FDA’s ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC lacking HRR mutations.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
Durvalumab added to BCG induction and maintenance improved disease-free survival vs BCG alone in high-risk non–muscle-invasive bladder cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
Durvalumab plus BCG induction/maintenance improved DFS vs BCG alone in NMIBC. Read more below. #oncology #bladdercancer #news #nursing https://t.co/82X9OFldvf
-
-
Mashup Score: 0
Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
The addition of panitumumab to neoadjuvant chemo improved outcomes for patients with locally advanced colon cancer. Read more below. #coloncancer #GIcancer #oncology #nurse https://t.co/B2JBmjPhlc
-
-
Mashup Score: 0
KEYNOTE-B96 showed pembrolizumab-based therapy improved PFS and OS in PD-L1–positive platinum-resistant ovarian cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
Pembrolizumab plus paclitaxel with or without bevacizumab improvied PFS in platinum-resistant ovarian cancer. Read more below. #ovariancancer #gyncSM #womenshealth #oncology #nurse https://t.co/TAMUR61T13
-
-
Mashup Score: 1
A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
🎥 Samantha Shenoy, MSN, NP, worked with providers at her institution and beyond to compile best practices on AE management for patients with multiple myeloma on talquetamab. #oncology #nurse #myeloma #interdisciplinarycare https://t.co/IOytiGIsTn
-
-
Mashup Score: 0
CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
CAR T-cell therapy CT0596 showed early efficacy and safety signs in patients with relapsed/refractory multiple myeloma. Read more below. #MMsm #myeloma #hematology #oncology #nurse https://t.co/m9XQvM3l2N
-
-
Mashup Score: 1
Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
Ribociclib plus endocrine therapy produced similar pCR rates to standard chemotherapy in HR-positive, HER2-negative breast cancer. Read more below. #BCsm #breastcancer #oncology #nurse https://t.co/Tz2UGFzbaJ
-
-
Mashup Score: 0
Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
Disitamab vedotin plus toripalimab increased PFS and OS in the first line of therapy for patients with HER2-positive metastatic urothelial cancer. Read more below. #bladdercancer #urothelialcancer #oncology #nurse https://t.co/6oaVrJZN5Q
-
-
Mashup Score: 0
The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
A nurse practitioner at @UCSFHospitals explained some of the factors that should be considered when selecting a frontline CDK4/6 inhibitor for HR+ breast cancer. Read more below. #BCsm #oncology #nursing https://t.co/guH4EYtwx4
-
-
Mashup Score: 0Ibrutinib/Nivolumab Yields Activity in Relapsed CNS Lymphoma - 8 day(s) ago
Three of 18 patients had remissions lasting over 2 years in a study of ibrutinib plus nivolumab for relapsed/refractory CNS lymphoma.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
The combination of ibrutinib and nivolumab showed efficacy and tolerability in patients with relapsed/refractory CNS lymphoma. Read more below. #oncology #lymphoma #nurse #nursing https://t.co/TzP1QaAP0V
-
ODAC Votes Against Talazoparib Combo for Patients With non-HRR mCRPC. Read more below: https://t.co/Veze1cdweY